RECENT NEWS

Life science imaging systems manufacturer Evident Corporation and Ultivue, an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, have announced a collaborative agreement to promote whole slide imaging using multiplexed immunofluorescence (mIF) assays to advance translational research in the Americas.

EnteroBiotix, a full-spectrum microbiome therapeutics company, has announced a partnership with Imperial College London to develop microbiome R&D in patients suffering from blood cancer as well as accelerate systematic research in the new science of the microbiome.

BIOHIT HealthCare is excited to be exhibiting at this year’s British Society for Immunology (BSI) Congress in Liverpool.

Diagnostica Stago is launching qLabs FIB - a novel POC device which measures fibrinogen levels from a single drop of whole blood, further expanding the company’s near-patient testing solutions for the critical care setting.

NHS patients throughout the West Midlands are to benefit from a digital pathology programme, designed to help reduce cancer backlogs, transform services, and improve the speed and accuracy of cancer diagnosis.

Red blood cells that have been grown in a laboratory have now been transfused into another person in a world first clinical trial. The manufactured blood cells were grown from stem cells from donors. The red cells were then transfused into volunteers in the RESTORE randomised controlled clinical trial.

A £2.4 million investment in state-of-the-art pathology automation solutions is helping to deliver improved care for millions of patients across the UK. SYNLAB has installed world-leading laboratory equipment at three of its NHS partnerships, which combined serve more than four million people.

Castle Biosciences has announced new data showing that the use of TissueCypher Barrett’s Esophagus Test results can significantly improve management decisions for Barrett’s oesophagus (BE) patients with low-grade dysplasia (LGD) to improve health outcomes.

Feline veterinary specialist Dr Samantha Taylor will be discussing the complexities of feline infectious peritonitis (FIP) at HORIBA’s latest free-to-attend online CPD webinar.

SYNLAB and Microba Life Sciences have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.

Roche has announced plans for the US launch of the cobas 5800 System, a compact, fully-automated molecular laboratory instrument that offers a flexible, PCR testing solution that aids clinicians in diagnosis of infectious diseases.

Global diagnostics company EKF Diagnostics, will be introducing its latest product developments and offerings at MEDICA 2022, Düsseldorf, Germany, 14-17 November.

Cleanroom microbiology solutions firm Cherwell Laboratories will be leading an open discussion on environmental monitoring (EM) in line with EU GMP Annex 1 at the forthcoming Pharmig 30th Annual Conference.

Proscia has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.

The PPD clinical research business of Thermo Fisher Scientific has unveiled plans to invest $59 million to significantly expand its laboratory operations in Highland Heights, Kentucky, USA over the next two years.

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Altasciences’ clinical site in Los Angeles, California, based on results of a recent on-site inspection.

Zürich University Hospital has started using Stockholm3 for prostate cancer testing. This is the first clinic in Switzerland that uses Stockholm3.

More companies around the world continue turning to Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, for their next-generation sequencing (NGS) needs with the Biomek NGeniuS System.

Thermo Fisher Scientific has announced that it has entered into a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion.

Three French university hospitals are to adopt the digital pathology solution from Sectra, joining forces to speed up cancer diagnostics.